ArticleMaterials today. Bio2025
A microfluidic tumor-on-chip platform deciphers hypoxia-driven FOXO3a/PD-L1 signaling in gastric cancer immunotherapy resistance.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Spatial architecture and dynamic surveillance: 3D bioprinting and microfluidics converge to overcome digestive malignancies.Hepatobiliary surgery and nutrition · 2026Article
- Gastric Cancer Organoids: Mechanistic Insights, Drug Discovery, and Translational Advances in Precision Medicine.Journal of gastric cancer · 2026Review
- A review of current evidence and perspectives on the mechanisms and clinical significance of hypoxia-induced remodeling of the gastric microbiota-metabolism axis.Frontiers in microbiology · 2026Review
- Characteristics and therapeutic resistance mechanisms of the prostate cancer immune microenvironment: a comprehensive analysis from bench to clinic.Frontiers in pharmacology · 2026Review
- Electrospun nanofibers for gastric cancer: local therapeutics, biomimetic models, and diagnostic interfaces.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia represents a common feature within the microenvironment of various cancerous tumors, which suppresses tumor immunogenicity. Immunotherapy, particularly based on immune checkpoint inhibitors, significantly alters the prognosis of certain tumors and reveals the presence of intrinsic or acquired resistance. Presently available platforms, however, cannot efficiently recapitulate the in vivo tumor microenvironment and elucidate the mechanisms of hypoxia-induced immunotherapy resistance in tumors. In this study, a microfluidic tumor-on-chip model is employed to investigate immunotherapy resistance in gastric cancer (GC) cells within a hypoxic microenvironment. Unlike traditional methods, this chip accurately and efficiently replicates the in vivo tumor hypoxic microenvironment. This microfluidic platform demonstrates the upregulation of the forkhead box O3 (FOXO3a) under hypoxic conditions, subsequently activating downstream programmed cell death ligand-1 (PD-L1) expression, ultimately leading to immunotherapy resistance. In a syngeneic mouse model, FOXO3a deficiency restores sensitivity to immunotherapy by enhancing immune cell enrichment. In clinical samples, FOXO3a levels and the prognosis of patients with gastric cancer receiving immunotherapy are correlated. In summary, by constructing a novel microfluidic chip, the in vivo tumor microenvironment can be efficiently simulated, uncovering the pivotal role of FOXO3a in immunotherapy resistance in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.